# Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03194685** · PHASE1 · COMPLETED · sponsor: **Fujifilm Pharmaceuticals U.S.A., Inc.** · enrollment: 97 (actual)

## Conditions studied

- AML, Adult

## Interventions

- **DRUG:** FF-10101-01

## Key facts

- **NCT ID:** NCT03194685
- **Lead sponsor:** Fujifilm Pharmaceuticals U.S.A., Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-05
- **Primary completion:** 2021-07-31
- **Final completion:** 2021-07-31
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2024-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03194685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03194685, "Study of FF-10101-01 in Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03194685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*